drugset / Trial / NCT03751423

Intravenous Ketamine for Pain Control During First Trimester Surgical Abortion

NCT03751423

Phase 3 Suspended 123 enrolled Dr. Marie Eve Sophie Bussiere-Cote
RandomizedParallel-groupTriple-blindSupportive care

Summary

A therapeutic abortion is one of the most common procedures performed in Canada, with approximately 100,000 occurring annually. 95% of induced abortions are done surgically, with just over two thirds of these procedures taking place in the first trimester. This study will be a randomized, controlled, double-blinded, single-centre superiority trial with three parallel groups; oral morphine vs intravenous fentanyl vs intravenous ketamine. The primary outcome will be immediate post-operative pain following a first trimester therapeutic abortion as assessed using the visual analogue scale. Randomization will be performed as block randomization with a 1:1:1 allocation ratio. In total, 123 participants will be recruited and randomized, with 41 being assigned to each treatment arm. This study will be conducted at the Women's Clinic at Kingston General Hospital in Kingston, Ontario, Canada. Women from Kingston and the surrounding areas are referred to this clinic and can self-refer for therapeutic abortion. The investogators hope that this research will move us towards a better form of pain control for our participants undergoing first trimester surgical abortion, without increasing length of stay, side effects, or adverse events. This, in turn, will hopefully improve access to optimal pain control to participants undergoing first trimester surgical abortion in an outpatient setting.

Timeline

Start
2019-06-10
Primary completion
2023-12-31
Completion
2023-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fentanyl Other / unclassified 0.5 ug/kg Intravenous
Comparator Fentanyl Other / unclassified 1 ug/kg Intravenous
Subject Ketamine Small molecule 200 ug/kg Intravenous
Subject Ketamine Small molecule 500 ug/kg Intravenous
Comparator Morphine Other / unclassified 10 mg Oral
Comparator Morphine Other / unclassified 20 mg Oral

Indications

No indication recorded.